A first-in-human single ascending dose study of a monoclonal antibody against the ANGPTL3/8 complex in subjects with mixed hyperlipidemia
D Gaudet, M Gonciarz, X Shen, G Mullins… - …, 2022 - atherosclerosis-journal.com
Methods: This 28-day, randomized, double-blind, placebo-controlled study enrolled 48
subjects (36 males/12 females) with TG> 135 mg/dL and LDL-C≥ 70 mg/dL who were
assigned (6: 2) to receive 1 dose of LY or placebo intravenously (10-30mg) or
subcutaneously (100-600mg). LY pharmacokinetics, fasting lipids, apolipoproteins, vital
signs, laboratory data, and adverse events (AEs) were measured. Results: LY reached
maximum concentration 27-108 hours after subcutaneous injection; half-life for 600mg LY …
subjects (36 males/12 females) with TG> 135 mg/dL and LDL-C≥ 70 mg/dL who were
assigned (6: 2) to receive 1 dose of LY or placebo intravenously (10-30mg) or
subcutaneously (100-600mg). LY pharmacokinetics, fasting lipids, apolipoproteins, vital
signs, laboratory data, and adverse events (AEs) were measured. Results: LY reached
maximum concentration 27-108 hours after subcutaneous injection; half-life for 600mg LY …